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Polyglutamine (polyQ) diseases are a group of pathologies that
lead to the dysfunction and eventual death of neurons in certain
areas of the brain. Nine diseases constitute this group: hunting-
ton’s disease (HD); spinocerebellar ataxias (SCA) type 1, type 2,
type 6, type 7, and type 17; Machado–Joseph disease (MJD/
SCA3), spinal and bulbar muscular atrophy X-linked type 1
(SMAX1/SBMA) and dentatorubralpallidoluysian atrophy (DRPLA).
The cause of these diseases is an expansion of CAG repeats in the
coding region of causative genes. Each disease has its own causa-
tive gene as well as the threshold number of repeats that leads
to pathology (Table 1). The frequency of polyQ diseases averages
1–10 cases per 100000 people but may be higher in certain re-
gions. For instance, many people in the large community living
around Lake Maracaibo in Venezuela were speciﬁcally diagnosed
with HD in the 1950s (for review, see [1]). Many cases of SCA2
were reported from Cuba; SCA3, from the Azores; SCA10, from
Mexico; DRPLA predominantly occurs in Japan [2–4], whereas HD
is more common in Western European populations. All these dis-
eases are autosomal dominantly inherited, except SMAX1/SBMA
which is linked to the mutation in the androgen receptor gene
located on the X chromosome [5].The proteins responsible for the diseases of this family are not
related to each other, differing in function and intracellular locali-
zation (Table 1). Nevertheless, polyQ diseases share many common
pathological features. First, their common attribute is CAG elonga-
tion in causative genes. Second, symptoms of these diseases usu-
ally appear at middle age and progressively worsen until death,
over about 15–20 years, with longer repeat sizes being associated
with an earlier age of disease onset [6]. Third, a pathological hall-
mark of all polyQ diseases is the presence of intracellular aggre-
gates (inclusion bodies) formed by mutant proteins in the brain.
In general, the mutant proteins are expressed throughout the body,
but selective degeneration is observed in speciﬁc regions of the
brain [7]. Finally, since CAG repeats tend to expand from genera-
tion, there is a phenomenon known as genetic anticipation, which
refers to the risk for asymptomatic patients to transmit the disease
to their children or, in general, for an earlier onset and increased
severity of the disease in the next generation [5].
The best studied pathology, HD, usually involves the loss of
neurons in the striatum and layers III and V of the cortex, which af-
fects muscle coordination and leads to cognitive impairment and
psychiatric problems. The IP15 gene that encodes the huntingtin
(Htt) protein is located on the 4th chromosome. This protein is
widely expressed in neuronal and non-neuronal tissues, but its
clevel in the striatum is higher than in other organs [8]. The func-
tions of normal Htt are not yet completely known. This is a large
protein containing a proline/glutamine-rich domain and three
HEAT regions at the N-terminal part of its molecule, all of them
Table 1
Polyglutamine-associated diseases and their causative genes/proteins.
PolyQ disease Culprit
protein
Gene and its localization Normal function
of protein
nCAG Most affected
CNS brain area
Huntington disease Huntingtin IP15, htt,
4
Cellular trafﬁcking
Scaffold protein
N: 7–35
P: 36–170
Striatum
SCA1 Ataxin-1 ATXN1
6p
Chromatin binding factor
Transciptinal co-repressor
N: 27–36
P: 39–82
Cerebellum
SCA2 Ataxin-2 ATNX2,
12q
Component of stress granules
Possible participation in gene
Translational repression in vivo
N:15–32
P: 36–64
Cerebellum
SCA3 Machado–Joseph
disease (MJD)
Ataxin-3 ATNX3,
14q24.3–32.2
Proteolytic processing of other proteins N: 12–43
P: 52–86
Spinal cord
SCA6 Calcium chanel CACNA1
19q
Alpha 1A subunit of the voltage
dependent P/Q type calcium channel
N: 8–14
P: 20–33
Cerebellum
SCA7 Ataxin-7 ATNX7,
3p
Ataxin-7 may play role in the
regulation of gene transcription
N:7–35
P: 38–200
Eye retina
SCA17 Tata-binding protein TBP
6q
General transcription initiation factor N: 24–44
P: 45–63
Cerebellum
SBMA (spinobulbular
muscular atrophy),
Kennedy disease
Androgen receptor AR
X-chromosome
Receptor N: 11–35
P: 38–62
Spinal cord and
brainstem
Dentatorubro
pallidolysian
atrophy
DRPLA protein or Atrophin-1 ATN1
DRPLA gene at 12p13.31
Transcription co-regulator N: 7–34
P: 48–93
Both the
dentatorubral and
pallidoluysian
systems
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ent in the nucleus, cell body, dendrites, and nerve terminals [10]. It
is suggested that non-mutated Htt is involved in cellular trafﬁcking
and can function as a scaffold protein [11].
Spinocerebellar ataxia types 1–3, 6, and 7 are the most frequent
among autosomal dominantly inherited cerebellar ataxia (ADCA)
syndromes and account for 50–60% of all families affected by ADCA
worldwide [12–14]. Major symptoms of ataxia, such as imbalance
and incoordination, are indicative of impairment of cerebellar
functions, which results mainly from a massive loss of Purkinje
cells. Ataxias are often accompanied by dysarthria, rigidity, and
dystonia, as well as by oculomotor disorders [15].
DPRLA is caused by a mutation in the atrophin-1 gene that re-
sults in an abnormally expanded polyQ tract in this protein. DRPLA
patients show a wide variety of progressive neurological deﬁcits
like ataxia, myoclonus, epilepsy, and dementia [16,17].
Spinal and bulbar muscular atrophy (SBMA), or Kennedy’s dis-
ease is characterized by slowly progressing muscle weakness and
atrophy of the bulbar, facial, and limb muscles. Pathologically,
SBMA is associated with the loss of motor neurons loss in the
spinal cord and brainstem [18]. SBMA is caused by an abnormal
expansion of CAG repeats in exon 1 of the androgen receptor
(AR) gene on chromosome Xq11–12 [19,20].
To understand the pathogenesis of the above disorders in detail,
approximately 100 genetic mouse models of polyQ diseases have
been created. Most of them deal with HD, while some ataxia types
(e.g., SCA6) have not yet received due attention. These models
show different degrees of similarity to human polyQ diseases. Of
special interest are transgenic mouse models expressing full-
length causative genes. Thus, YAC transgenic mice with the yeast
artiﬁcial chromosome carrying the htt gene with 18, 46, 72, or
128 CAG repeats almost completely reproduce the features of hu-
man HD (for review, see [5]). Another example are B05 mice in
which the ataxin-1 gene is under the control of the proximal pro-
moter of a Purkinje cell-speciﬁc gene (Pcp2/L7), and the gene prod-
uct (ataxin-1 with 82 CAGs) is therefore expressed only in Purkinje
cells [21]. Biochemical changes observed in B05 mice are similar to
those in SCA1 patients [22]. In mouse models such as R6/1, R6/2,
and R6/5, only exon 1 of the mutant htt gene with expanded CAGs
is expressed (for review, see [5]). In other models the culprit gene
is chimeric, i.e., consists of a hybrid mouse/human DNA sequencewith elongated CAG repeats. In HdhQ92 and HdhQ111 mice, for
example, exon 1 of the htt gene was functionally replaced by
knock-in of such a hybrid mouse/human sequence with 50, 92,
or 111 CAG repeats [23,24].
A new technology for modeling polyQ diseases, which has been
developed during the past 5 years, is based on the use of induced
pluripotent cells (IPC). Fibroblasts from patients are reprogrammed
in vitro using lenti- or retroviral vectors carrying genes such as
Oct4, Klf4, Sox2 and c-Myc, whose expression is characteristic of
natural pluripotent cells, including embryonic stem cells. Thereaf-
ter, the medium is supplemented with neuronal differentiation fac-
tors (e.g., BDNF) to induce the conversion of reprogrammed cells
into functional neurons. The resulting cell culture most closely
resembles neurons affected by a given polyQ pathology.
The ﬁrst cell culture from a neurological patient was described
by Park et al. [25]. To date, several neuronal cell lines from patients
with SCA2 and HD have been established and characterized. Cam-
nasio with colleagues (2012) obtained neuronal cell cultures from
two rare homozygous HD patients with 42/44 and 39/42 CAGs, a
heterozygous patient with 17/45 CAGs, and a healthy adult with
15/17 CAGs. They found that the length of the pathological CAG
tract did not increase during cell reprogramming and after long
term growth in vitro and differentiation into neurons. Neither were
any differences observed between cells with normal and mutant
genotypes when comparing them with respect rates of reprogram-
ming, growth, or neuronal differentiation. However, a signiﬁcant
increase in lysosomal activity was noted in HD-IPCs, compared to
control IPCs, both during self-renewal and after conversion into
neurons [26]. In experiments with a neuronal line from as SCA2 pa-
tient [27] SCA2 and normal ﬁbroblasts showed comparable levels of
ataxin-2 expression, whereas this level in SCA2 neural stem cells
was lower than in normal neural stem cells and SCA2 ﬁbroblasts.
According to the results of time-lapse assay, terminally differenti-
ated SCA2 neural cells were short-lived, compared to control neural
cells. In another study, IPCs were generated from ﬁbroblasts of R6/2
mice (with htt exon 1 containing 144 CAGs) and reprogrammed to
neurons. None of three resulting HD-IPC clones did demonstrate
aggregation; after10 days of neuronal differentiation, however,
EM48-positive Htt inclusions were detected in GAP-43-positive
mature neurons. The observation that cultured ﬁbroblasts and plu-
ripotent cells were devoid of aggregates while differentiating cells
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cess allows retention of the mutant protein in an aggregate-prone
state. Moreover, these data demonstrate that HD-IPC recapitulate
some HD phenotypes linked to transcriptional alteration of
genes involved in cholesterol biosynthesis and lysosomal biogene-
sis [28].
Thus, novel approaches and models proposed in the past few
years provide the possibility to study polyglutamine-associated
diseases at the cell level and apply the results of such studies di-
rectly to the screening of potential drugs on cell platforms.
2. Functions of polyQ-containing polypeptides
The development of PolyQ-mediated pathology at the cell level
is a multiphase process starting with the appearance of a mutant
protein in the cytoplasm. The protein then assembles into oligo-
mers and, because of misfolding, accumulates into aggregates,
forming inclusion bodies (aggresomes). Finally, polyQ oligomers/
aggregates are released to the extracellular medium and are
trapped by an acceptor neuron [29,30], (Fig. 1).
It is known that a mutant polyQ protein in a soluble monomeric
form affects the functions of several other important proteins, and
these effects are usually discussed in terms of gain- or loss-of-func-
tion phenotype [31]. As to gain of function, mutant Htt was found
to acquire the ability to interact with several proteins, including
the Htt-associated protein (HAP1), Htt-interacting protein (HIP1)
[32], and proteins responsible for the synaptic function. HAP1 is
an essential component of the stigmoid body (STB), and it has been
found that the HAP1/STB complex interacts with the normal atax-
in-3 through Josephin domain and polyglutamine-expanded mu-
tants derived from SCA3, indicating that HAP1/STB can modify
the physiological function of normal ataxin-3 and promote SCA3
pathogenesis [33]. A good example of the loss-of-function pheno-
type of mutant polyQ protein comes from the analysis of HIP1Fig. 1. Aggregation of polyQ proteins and their particular targets in a neural cell. The agg
its each stage the pathogenic structures threaten cell physiology by sequestering or mo
polyQ proteins target various signaling systems mainly mitochondria and membrane stru
cytosol and cell nuclei, the latter are especially cytotoxic. PolyQ proteins in aggregate form
regulators, chaperone and other elements of proteastasis system. To cope with the toxic p
with lysosomes. A part of polyQ oligomers or aggregates can be released from a cell andactivity. As the number of glutamine repeats in mutant Htt in-
creases, HIP1 loses its ability to bind this protein and starts to
interact with Hippi1 (HIP1 protein interactor), and this complex
activates caspase 8, which leads to apoptosis [34].
The well-documented property of mutant polyQ proteins is
their ability to reduce the activity of several important cell recep-
tors, including those participating in calcium signaling [35]. Previ-
ous studies on polypeptides whose level can be reduced
concomitantly with the elevation of mutant Htt expression re-
sulted in identiﬁcation of proteins involved in the regulation of cal-
cium homeostasis: hippocalcin, calcineurin, ryanodine receptor
(RyR), inositol-1,4,5-trisphosphate receptor type 1 (InsP3R1), and
calcium/calmodulin-depended protein kinase [36,37]. It has been
recently reported that the expression of full-length mutant Htt in
YAC128 mouse embryonic ﬁbroblasts resulted in impaired mito-
chondrial calcium loading and a twofold higher level of mitochon-
drial genomic DNA damage due to the excessive oxidant
generation [38].
The main intracellular calcium stores are localized in the endo-
plasmic reticulum (ER). Mutant Htt was found to directly interact
with type 1 inositol-1,4,5-trisphosphate receptor (InsP3R1) on
the ER membrane surface, the interaction being dependent on
the presence of HAP1 and of the long polyglutamine tract within
mutant Htt [39]. The increased afﬁnity of the latter to the receptor
can lead to the depletion of calcium stores in response to basal con-
centration of InsP3. It has been shown that destabilization of the
interaction between mutant Htt and InsP3R1 protects MSNs in an
HD mouse model [40]. Furthermore, inhibition of InsP3R1 activity
has been found to reduce aggregation of pathogenic polyQ pro-
teins, suggesting a direct link between impaired calcium signaling
and mutant Htt expression [41].
Calcium channels of the plasma membrane are also affected in
HD pathogenesis. The expression of mutant Htt increases the activ-
ity of the NMDA receptor, NMDAR [42,43], which, in turn, canregation of polyglutamine tract-containing proteins is a multiphasic process, and at
difying client proteins and defying cell physiology. At the ﬁrst stage monomers of
ctures. Monomers in an appropriate concentration start to form oligomers located in
sequester a number of important for cell viability proteins including transcription
olyQ protein species a cell encapsulates them into membranous structure associated
penetrate inside another one thus triggering transmission of a disease.
Table 2
PolyQ protein interactors as therapeutic targets (see text for details).
Stage Targets Drug References
Monomeric PolyQ InsP3R1 inhibition reduces mutant Htt aggregation 2-aminoethyl di phenylborinate (2-APB) [41]
NMDAR inhibition leads to neutoprotective effect 2-APB, Enoxaparin (Lovenox) [44,45]
Calpain activation leads to change of NMDAR localization and apoptosis Calpain inhibitor calpeptin [46]
Inhibition of store-operated calcium (SOC) pathway leads to neuroprotection Quinazoline [47]
Inhibition of mitochondrial membrane permeability and cytoprotection Inhibitors of cytochrome c release [50]
SIRT3 expression synthesis ()-e-vineferin [51]
GSK3 inhibition leads to neuron survival in HD model SB21676 [53]
Oligomers Inhibition of Htt oligomerization Intrabody scFv-C4 [127]
Inhibition of Htt oligomerization QBP1 peptide [133]
Inhibition of Htt oligomerization Peptinoid HQP09 [134]
Inhibition of mHtt cleavage Calpain inhibitors
Caspase inhibitors
[137]
Aggregates Inhibition of tTG activity cystamine [68]
GAPDH binding GAGDH binders
Pefablock,
Deprinil
[77]
Inducing molecular chaperones NG-094 [138]
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inhibition of NMDAR proved to have a neuroprotective effect in
striatal neurons isolated from the transgenic HD mouse [44,45].
Recently, it has been reported that increased STriatal-Enriched pro-
tein tyrosine Phosphatase (STEP) and calpain activation contribute
to altered NMDAR localization in an HD mouse model, suggesting
STEP and protease as new therapeutic targets for HD treatment
[46].
Store-operated calcium (SOC) channels, identiﬁed as an impor-
tant and ubiquitous mechanism for calcium inﬂux in mammalian
cells, have proved to be activated in a HD model based on human
neuroblastoma cells. Quinazoline derivatives have been shown to
inhibit the SOC pathway involving TPRC1 channels, suggesting
TPRC1 to be a novel drug target in the treatment of HD and other
polyglutamine diseases [47], Table 2.
Mitochondria appear to be an ubiquitous target for the mutant
Htt, since this protein has been shown to directly interact with the
mitochondrial membrane to cause opening of the permeability
transition pore (PTP), which contributes to the calcium release
[48]. It has been suggested that activation of the PTP plays a crucial
role in cell death [49]. Inhibitors of mitochondrial membrane per-
meability have a neuroprotective effect in cellular and mouse HD
models [50]. Another prospective target for HD therapy is mito-
chondrial protein SIRT3, a member of the sirtuin family. It has been
found that the level of SIRT3 in cells expressing mutant Htt is re-
duced but can be restored by administration of trans-()-e-vinifer-
in, with the drug showing a potent neuroprotective effect [51].
Glycogen synthase kinase-3 (GSK-3) is another important pro-
tein known to interact or co-localize with mutant Htt. The overex-
pression of this enzyme results in increased rates of polyQ
aggregate formation and cell death [52]. As recently reported by
Valencia et al. [53], GSK-3 co-localizes with mutant Htt containing
a 150Q tract in lipid rafts of the membranes of nerve cells in trans-
genic mice. Moreover, high levels of GSK-3 are associated with the
progressive death of neurons, while the inhibition of the enzyme
activity can alleviate corresponding pathological symptoms.
Thus, mutant polyQ polypeptides can adopt a number of differ-
ent conformations [54], some of them directly affecting vital pro-
teins and their functions in a neural a cell. An important fact is
that, in some cases, inhibition of the protein affected by a mutant
polyQ polypeptide can reduce pathological manifestations. In other
words, there exists a linkage between the causative polypeptide
and its target protein that can be regulated by a certain substance;
the examples of such pro-drugs are trans-()-e-viniferin and val-
proic acid, known inhibitor of GSK-3. It is also noteworthy that partof the initial population of polyQ protein monomers can be con-
verted into cytotoxic molecules damaging cell proteins and inhib-
iting their activities. Another part of the initial pool, consisting of
non-functional proteins, can be processed/digested by cellular pro-
teostasis mechanisms or remain untouched to form oligomeric or
aggregate structures that can affect cell physiology.
3. Oligomerization and aggregation of polyQ proteins
The most important property of polyQ proteins is their propen-
sity to form cytotoxic oligomers and aggregates (Fig. 1).
The accumulation of polyQ protein monomers leads to the next
stage of pathogenic process, which begins from the processing of
above polypeptides by speciﬁc proteases, calpain and caspases,
which excise polyQ sequences from host proteins. Wellington
et al.[55] found mutant Htt to be a speciﬁc target for caspase 2 at-
tack, with the site of proteolysis being located at amino acid posi-
tion 552 both in vitro and in brain samples from HD patients and
YAC72 transgenic HD mice. Cleaved Htt was detected in wild-type
and HD transgenic mouse brains before the onset of neurodegener-
ation, suggesting that caspase 2-mediated cleavage may be a nor-
mal physiological event. However, the cleavage of mutant protein
was shown to result in the release of N-terminal fragments with
a potential for increased toxicity [55]. Ataxin-3 can be also cleaved
by caspase 1, with the inhibitors of the enzyme speciﬁcally reduc-
ing the cleavage. Berke et al. [56] showed that caspase-mediated
cleavage of expanded ataxin-3 resulted in increased ataxin-3
aggregation, suggesting a potential role for caspase-mediated pro-
teolysis in SCA-3 pathogenesis. Likewise, caspase-7 was found to
cleave ataxin-7, the pathogenic protein in SCA-7, and two putative
caspase-7 attack sites were mapped at positions 266 and 344 of the
ataxin-7 sequence [57].
Calpains were also shown to cleave polyQ proteins and produce
short mutant Htt fragments highly toxic for striatal cells. Increased
concentrations of calpain family members—calpain-1, -5, -7, and -
10—were found in HD tissue culture and transgenic mouse models,
suggesting that they may play a role in Htt proteolysis and disease
pathology [58]. Recent results indicate a role for calpain-2 in the
selective proteolysis of ataxin-3 (SCA3). First, the enzyme was
found to selectively cleave ataxin-3 in vitro. Second, double-
mutant mice with a knockout of endogenous calpain inhibitor, cal-
pastatin, and up-regulated ataxin-3 demonstrated an aggravated
neurological phenotype characterized by an increased number of
nuclear aggregates and accelerated neurodegeneration in the cere-
bellum [59]. Finally, proteolytic enzymes, caspases and calpains,
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polypeptides, especially those localized to the nuclei, are especially
dangerous because of their ability to exacerbate the effects de-
scribed in Section 2. The data discussed above also show that cas-
pase or calpain inhibitors may be effective factors in the therapy of
polyQ-associated pathologies, especially at their early stages
(Fig. 1).
Oligomerization of polyQ tracts excised from the mutant pro-
teins appears to be a prerequisite for their accumulation into large
aggregates. Oligomeric polyQ subunits may be of several types.
Shorter subunits consisting of pure Htt fragments form b-struc-
tures (b-strands or b-turns), while larger polyQ chains are con-
verted into globular structures as being produced from ﬁbrils
[60]. The pathogenic role of polyQ chain oligomerization was con-
ﬁrmed by Sánchez et al. [61], who demonstrated that Congo red,
known for strong binding to polyQ chains, inhibited ATP depletion
and caspase activation; moreover, the dye was shown to reconsti-
tute normal protein synthesis and the clearance of expanded gluta-
mine repeats in vitro and in vivo.
Oligomers of polyQ tracts can further form aggregates differing
in form and size. The process of aggregation implies the stage of
nucleation at one or several sites in the cytoplasm [29]. According
to the ‘‘polar zippers’’ model, polyQ polypeptides can form b-sheet
structures where every 20 amino acids are folded in an antiparallel
manner and these antiparallel tracts are connected by hydrogen
bonds between their amides. These zipper-like structures may
serve as nucleation seeds for the formation of aggregates [62,63].
To prevent aggregation, it may prove expedient to use certain tools
of conformational therapeutics (the term used by Ross and Tabrisi,
[64]. Some of them are described in the next section.
In another model of aggregation, glutamines of a causative pro-
tein (e.g., Htt) are covalently linked to lysines of other proteins via
a process catalyzed by tissue transglutaminase (tTG) [65,66]. tTG
belongs to the group of closely related enzymes that share the
ability to catalyze the cross-linking of a glutaminyl residue of a
protein/peptide substrate to a lysyl residue of a protein/peptide
co-substrate [67]. The involvement of tTG in the pathogenesis of
HD is conﬁrmed by the observation that cystamine, a tTG inhibitor,
markedly improves locomotor functions and survival of animals in
mouse models of HD, providing evidence for the pharmacological
potential of speciﬁc inhibitors of this enzyme [68], (Table 2). It
has also been demonstrated that caspase-mediated excision of pol-
yQ tracts from the pathogenic protein is a prerequisite for the tTG
reaction [69]. Subsequent cross-linking of glutamines to lysines by
tTG leads to the formation of aggregates that cannot be dissolved
by strong denaturants, such as sodium dodecylsulfate or guanidine
hydrochloride [66]. Recent experiments of Bortvedt et al. [70] with
a transgenic Drosophila HD model expressing a transgene encoding
an intracellular anti-Htt single-chain Fv antibody (C4-scFv intra-
body) in the nervous system showed that feeding cystamine to
adult HD ﬂies resulted in a signiﬁcant reduction of photoreceptor
neurodegeneration, without any improvement in longevity, while
feeding cystamine during both larval and adult stages produced
the converse result: longevity was signiﬁcantly improved, but no
increase in photoreceptor survival was observed.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a ubiq-
uitous cellular enzyme, was found to be a potential source of
amines for tTG [71]. In particular, tTG can utilize three lysine res-
idues of GAPDH (K191, K270 and K333), covalently linking them
to both long (43 aa) and short (17 aa) polyglutamine peptides
[72]. GAPDH has been implicated in the pathogenesis of polyQ dis-
eases [73,74]. PolyQ-associated aggregation of GAPDH was re-
ported in cell models of HD, SCA-1, and SBMA [75]. Interestingly,
GAPDH was found to speciﬁcally interact with proteins containing
polyQ domain, whereas deletion of the polyP region in the N-ter-
minal domain of Htt had no effect on the co-localization of thetwo proteins [76] and mutant Htt aggregates. Our recent data con-
ﬁrm that GAPDH is closely associated with the aggregation of pol-
yQ-containing protein: in a cell-free model of HD, the addition of
pure GAPDH increased polyQ aggregation, while immunodepletion
of GAPDH dose-dependently reduced the amount of SDS-insoluble
aggregates. Importantly, pharmacological GAPDH-binding sub-
stances were also shown to reduce polyQ-associated aggregation
in SK–N–SH neuroblastoma cells [77]. It is noteworthy that GAPDH
was also implicated in aggregation of mutant SOD1 (G93A) in a cell
model of familial amyotrophic lateral sclerosis: both speciﬁc anti-
GAPDH siRNA and GAPDH binder hydroxynonnenal inhibitor de-
creased aggregates of mutant SOD1 in ﬁlter trap assay [78].
Thus, at least two mechanisms are involved in the process of
aggregation of polyQ proteins, and we consider that both of them
operate in pathogenic neurons. Accordingly, it appears that an
effective countermeasure is to employ not only molecules recog-
nizing and binding a mutant polyQ protein, but also molecules that
target polyQ-binding polypeptides and thereby promote aggrega-
tion, as suggested above for GAPDH (Table 2).
In addition to GAPDH, a number of other cellular proteins are
sequestered by growing aggregates of polyQ proteins. The most
important among them are p300, CREB binding protein (CBP),
and p300/CBP-associated factor (Pcaf), whose acetyltransferase do-
mains are recognized by exon-1 of mutant Htt. Sequestration
inhibits their activity, which, in turn, reduces the level of histone
H3 and H4 acetylation, thereby causing an increase in cell death le-
vel [79]. As recently shown by Bodai et al. [80], the expression of
mutant htt exon 1 in Drosophila results in a reduced level of Pcaf,
and this reduction is associated with increases degeneration of
photoreceptor neurons. Importantly, inhibitors of histone deace-
tylase proved to reverse degenerative effects associated with the
down-regulation ofacetyl transferases and reduce lethality in two
Drosophila models of polyQ disease [81]. Another group of data
conﬁrms the signiﬁcance of deacetylation in a heterozygous mouse
knock-in model of HD with early cognitive deﬁcits. Such deﬁcits
(e.g., impairment of long-term spatial and recognition memory)
are often observed in human HD patients. The expression of mu-
tant Htt with 111Q in mice caused not only cognitive defects but
also reduction of histone H3 acetylation and expression of the
CREB/CBP gene as well as of c-fos, Arc, and Nr4a2 target genes re-
lated to memory. Consistently with the role of CBP in cognitive
impairment, histone deacetylase inhibitor trichostatin A proved
to rescue memory deﬁcits and recover transcription of CREB/CBP
target genes in these mice, indicating that drugs with deacetylating
activity can provide a new approach to the treatment of memory
deﬁcit in polyQ diseases [82].
In is noteworthy that, in addition to histones H3 and H4, polyQ
proteins themselves are targets for hyperacetylation that occurs
due to dysfunction of acetyltransferases in cells expressing such
proteins. Montie et al. [83] found that hyperacetylation of the mu-
tant androgen receptor with a long polyQ tract contributed to its
neurotoxicity, with pharmacological blockade of acetylation being
effective in reducing mutant AR aggregation. These authors also
showed that nuclear protein SIRT1, a natural deacetylase, exerted
neuroprotective effect by deacetylating AR at lysines 630, 632
and 633, which is evidence that SIRT1 and hyperacetylation are
promising targets for drug design (Table 2).
Growing aggregates consisting of polyQ proteins can be ob-
served as inclusions in different cytoplasmic locations, while a con-
siderable part of their population usually occurs in the cell nuclei.
These inclusions can arise from polyQ mono- or oligomers that are
processed by calpains, caspases or metalloproteases and trans-
ported to the nucleus, where they ﬁnally aggregate [84,31]. The
Htt molecule contains nuclear export signal (NES) within the ﬁrst
17N-terminal amino acids, with point mutations in this site caus-
ing an increase in polyQ intranuclear inclusions as well as in the
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aggregates can be delivered to the nucleus in complex with other
cellular molecules. In experiments with in vitro HD models, aggre-
gates derived from short sections of the htt gene could be detected
both in the cytosol and in the nucleus soon after transfection,
whereas at later stages the aggregates were localized exclusively
in the nucleus [86]. Bae et al. [87] demonstrated that polyQ aggre-
gates can be transported to the nuclei. In particular, they found
that Htt with 148Q, GAPDH, and Siah1 ubiquitin-E3-ligase could
form a ternary complex possessing a nuclear localization signal
(NLS). Overexpression of GAPDH or Siah1 enhanced nuclear trans-
location of mutant Htt and cytotoxicity, whereas GAPDH mutants
incapable of binding Siah1 proved to prevent translocation. Finally,
depletion of GAPDH or Siah1 by RNA interference reduced nuclear
translocation of mutant Htt and cytotoxicity.
As indicated earlier, polyQ monomers and oligomers are able to
bind acetyltransferases and inhibit their transcriptional activities.
Recently, mutant Htt itself was found to down-regulate transcrip-
tion of several genes by directly binding to multiple components of
the transcriptional machinery in a speciﬁc way [88]. A similar ef-
fect of gene promoter targeting was demonstrated in astrocytes
overexpressing mutant ataxin-7 (SCA-7). It was found that the
gene coding for reelin, a factor involved in the development of Pur-
kinje cells and of the cerebellum as a whole, is an ataxin-7 target
gene. The treatment of cells with trichostatin A, a histone deacetyl-
ase inhibitor, restored the expression of the reelin gene, suggesting
a pro-survival effect for sequestration of mutant ataxin-7 away
from promoters into nuclear inclusions [89]. Mutant androgen
receptor was also shown to target intranuclear protein PTIP (Pax
Transactivation-domain Interacting Protein), which contains an
unusually long glutamine-rich domain and is involved in DNA
repair. The expression of poly-Q AR sequestered PTIP away from
radiation-induced nuclear foci, with consequent sensitization to
DNA-damaging agents and chromosomal instability. In a mouse
model of SBMA, the removal of one copy of PTIP gene resulted in
symptoms of DNA damage in the muscle cell nuclei and acceler-
ated muscular atrophy [90]. Taken together, the data on nuclear
targets for polyQ proteins provide a new insight into the mecha-
nisms of their cytotoxicity. In our opinion, new approaches to the
treatment of polyQ diseases may well be focused on compounds
that strongly bind to sequences functioning as NLS or NES in the
above polypeptides.
Aggregates of polyQ-related proteins can form so-called aggre-
somes, large inclusions localized to juxtanuclear space. This is con-
sidered to be a form of cytoprotective response aimed at
sequestering potentially toxic misfolded proteins and facilitating
their clearance by autophagy (for review, see [91]). Aggresome for-
mation is mediated by dynein/dynactin microtubule-based trans-
port of misfolded proteins to the centrosome and involves
several regulators, including histone deacetylase 6, E3 ubiquitin-
protein ligase parkin and ubiquitin-1. In experiments by Taylor
et al. [92], mutant androgen receptor, which forms insoluble aggre-
gates and is toxic to cultured cells, was also found to form aggre-
somes (in a process different from aggregation), and this process
was disrupted by molecular and pharmacological interventions
to reveal their cytoprotective potential. Aggresome-forming pro-
teins proved to have an accelerated turnover rate, which was slo-
wed down by inhibition of aggresome formation, and aggresomes
were found to associate with lysosomal structures, suggesting their
contribution to degradation of toxic proteins. Aggresome forma-
tion is dependent on the presence of so-called P-region, a pro-
line-rich fragment of mutant Htt, and its N-terminal 17-aa
domain; in addition, a number of proteins have earlier been shown
to be critical for the process of aggresome maturation and target-
ing, including Cdc48 (VCP/p97) and its cofactors, Ufd1 and Nlp4
[93]. It is noteworthy that one of polyQ proteins, ataxin-3 (SCA-3), was found to regulate aggresome formation due to its deubiqui-
tinating activity. Todi et al. [94] identiﬁed Lys-117 as the primary
site of ubiquitination in wild-type and pathogenic ataxin-3 and
showed that ubiquitin-dependent activation of ataxin-3 at Lys-
117 is important for reducing the level of high-molecular-weight
ubiquitinated species and promoting aggresome formation in the
cells. Thus, aggresomes are apparently a reservoir where cytotoxic
protein species are sequestered to be degraded and removed with
the aid of lysosomes. The mechanism for the elimination of polyQ
proteins by autophagy will be discussed in the next section.
During the past few years, the idea of prion-like mechanism of
neurodegenerative disease propagation has become popular, and
evidence has been obtained that polyQ proteins can migrate from
one cell to another (for review, see [95]). Ren et al. [30] reported
that aggregates of a polyQ peptide (K2Q44K2) added to a cell culture
were efﬁciently internalized by living cells, accessed the cytosolic
compartment, attached to the actin cortex, and induced local redis-
tribution of intracellular Htt domain with a 25Q repeat. It is note-
worthy that the exogenous polyQ peptide induced the formation of
aggregates consisting of Q25 or Q71 Htt domain reporters, whereas
no such phenomenon was observed with two other prion-like pro-
teins, Sup35 and b-amyloid peptide 1–40 [30]. Recently, the pro-
cess of polyQ tract binding and internalization has been analyzed
in more detail to show that its intracellular transport is dependent
on proteins located on the cell surface and on the structure of pol-
yQ peptide itself [96]. The transmission of polyQ between neural
cells can explain why the pathology attributed to a certain brain
region, the striatum or hippocampus, can spread throughout the
brain tissue. The search for factors capable of preventing intercel-
lular transmission of protein pathogens becomes a new challenge
for specialists in relevant ﬁelds.4. Proteostasis mechanisms in polyQ-expressing cells
Neural cells with growing polyQ aggregates suffer stress caused
by a variety of factors: wrong signaling,dysfunction of protein syn-
thesis/modiﬁcation/utilization machineries, disturbances in trans-
port mechanisms, etc. Many of these factors appear to be related
to disruption of proteostasis under the effect of a pathogenic pro-
tein containing a long polyglutamine tract [97]. Indeed, every cell
possesses mechanisms necessary to cope with the above stressors
(proteasomal and lysosomal systems, chaperones, etc.), and the
question is whether the cell can switch on the appropriate protec-
tive system and make it function properly.
Some data published early in this century indicate that not all
the systems of protein quality control are efﬁciently functioning
in the cells synthesizing proteins with long polyQ tracts.
Jana et al. [98] found that the activity of proteasomes in mouse
Neuro-2A cells (inducibly expressing 60Q repeats) was inhibited
and that this was accompanied by damage to mitochondrial
membranes, release of cytochrome c, and further activation of cas-
pase-9- and caspase-3. The malfunction of proteasomes can be
associated with their inability to recognize ubiquitinated sub-
strates. In particular, such a phenomenon was observed in cells
overexpressing mutant ataxin-1: protesome-mediated turnover
of highly ubiquitinated ataxin-1 nuclear inclusions was consider-
ably lower than that of inclusions with a reduced ubiquitin con-
tent. Moreover, 26S and 20S eukaryotic proteasomes were unable
to process larger polyglutamine tracts (over 38 glutamine resi-
dues), and this fact was proposed as an possible explanation for
the early disease onset [99]. The authors of other study used
d2EGFP, a short-lived enhanced green ﬂuorescent protein, to ﬁnd
out whether polyglutamine-expanded ataxin-1 affects the function
of the proteasome. The results showed that d2EGFP was degraded
to a lesser extent in cells overexpressing ataxin 1 with a 82Q tract
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ataxin 1 gene resulted in reduced aggregation of the chimera pro-
tein and enhanced stability of d2EGFP peptide, conﬁrming the di-
rect effect of aggregating ataxin 1 on proteasome activity [100].
More recent data indicate that the polyQ-mediated inhibition of
the ubiquitin-proteasome system (UPS) is not inevitable. First,
Maynard et al. [101] showed that, although the expression of
mutant Htt resulted in general UPS inhibition in PC12 cells, there
was no increase in the level of proteasome reporter substrate in
the brain of R6/2 and R6/1 HD model mice. Secondly, it was found
that restoration of UPS activity after its global in vivo correlated
with the appearance of inclusion bodies, but these events did not
occur in cell and animal models of HD if inhibitors of polyQ aggre-
gation were administered [102]. Third, it was conﬁrmed that path-
ogenic accumulation of ubiquitin conjugates (usually attributed to
polyQ protein expression) is actually due to 26S proteasome inhi-
bition. In contrast to the above data, Hipp et al. [103] found that
the N-terminal fragment of mutant Htt did not block the protea-
somes and was recruited to cytoplasmic inclusions initially void
of ubiquitin. In their opinion, ubiquitin accumulation was linked
to the impaired functioning of cell proteostasis machinery rather
than to mutant Htt expression.
In addition to ubiquitination, polyQ proteins can undergo
SUMOylation, whose effects on mutant polypeptides is ambiguous.
Subramaniam et al. [104] reported that the small guanine nucleo-
tide-binding protein Rhes, selectively localized to the striatum,
bound to mutant Htt and induced its SUMOylation. This modiﬁca-
tion resulted in increased cytotoxicity, suggesting that Rhes–mHtt
interactions may be involved in the localized neuropathology of
HD. In contrast, modiﬁcation of another polyQ protein, ataxin-7
(SCA7), with SUMO1 and SUMO2 was reported to modulate the
aggregated state of the protein, whereas mutation of the SUMO-
recognition site on the ataxin-7 molecule resulted in the increased
amounts of both SDS-insoluble aggregates and caspase-3 positive
non-homogeneous intranuclear inclusions particularly toxic to
the cells [105].
One of the most efﬁcient mechanisms of toxic protein clearance
is autophagy. This process involves targeting of harmful or unnec-
essary cytoplasmic components and their isolation in newly
formed membrane structures named autophagosomes, which are
then fused with lysosomes and degraded by extremely active lyso-
somal hydrolases and proteases. The key factor regulating autoph-
agy is serine threonine kinase mTOR, which can form two
functionally distinct multiprotein complexes, mTORC1 (a regulator
of cell growth) and mTORC2 (an activator of pro-survival kinase
Akt) (for review, see [106]). Selective inhibitors of mTORC1 but
not of mTORC2 are rapamycin and its derivatives, everolimus and
CCI- 779. Studies on cell culture and transgenic mouse models of
HD and on the human brain have shown that mTOR is sequestered
in polyglutamine aggregates, which leads to the impairment of its
kinase activity and consequent enhancement of autophagy and
clearance of mutant Htt fragments. Rapamycin as an inhibitor of
mTOR kinase activity produces a similar effect, i.e., improves the
efﬁciency of autophagy and reduces Htt aggregate accumulation
and cell death [107]. In contrast to data on strong effects of rapa-
mycin, Roscic et al. [108] found that the allosteric inhibition of
mTORC1 alone by everolimus, a rapamycin analog, had no stimu-
lating effect on autophagy or polyQ aggregate degradation, with
the efﬁcient clearance of mutant Htt aggregates being achieved
only when catalytic inhibitors of both mTOR complexes, mTORC1
and mTORC2, were used. Several novel modulators of mTOR activ-
ity were identiﬁed when screening the substances capable of
affecting rapamycin-mediated cytostatic activity in yeast cells.
Three compounds induced autophagy in mammalian cells, enhanc-
ing the clearance of mutant Htt and acting independently of the
target for rapamycin [109]. A new means to induce autophagyhas been found by Shoji-Kawata et al. [110]. This is TAT-beclin 1,
a peptide derived from a region of the autophagy protein beclin
1, which binds human immunodeﬁciency virus (HIV)-1 Nef. The
peptide has been shown to reduce the accumulation of polyQ pro-
tein aggregates as well as the replication of several pathogens,
including HIV-1. The authors suggest that this peptide can become
a good therapeutic factor for treating different human pathologies.
Thus, induction of autophagy is a promising approach to the treat-
ment of polyQ-associated pathologies, the more so that many sub-
stances with such an activity have already been identiﬁed.
Another cell system responsible for protein folding control and
maintenance of cellular proteostasis is based on molecular chaper-
ones [111]. The expression of chaperones involved in polyQ dis-
eases—Hsp70, Hdj1/2 and Hsp104—can be induced by a variety
of stressful and pathogenic stimuli. The biosynthesis of Hsp chap-
erones is regulated by speciﬁc transcription factors (HSFs) recog-
nizing heat shock elements (HSE) (50-CNNGAANNTTCNNG-30).
Upon binding to HSE, HSF summons RNA polymerase II complex
to the appropriate hsp gene. Activation of HSF includes several
steps of conformational transitions, trimerization, phosphoryla-
tion, and other regulatory events [112].
In cells with mutant Htt, the level of heat shock transcription
factor 1 (HSF1) is reduced and, as a consequence, these cells have
an impaired heat shock response. The reduced levels of HSF1 and
Hsp70 have been revealed in the striatum of HD knock-in mice
when compared to wild-type mice [113].
Conversely, the inducible elevation of Hsp70 in neuroblastoma
cells expressing the htt gene exon 1 with 103Q, resulted in a
dose-dependent decrease in aggregate formation [77], and exoge-
nously delivered pure Hsp70 was also able to prevent the growth
of aggregates [114]. In a recent study by Shieh and Bonini [115],
a high level of Hsp70 expression protected SCA3 ﬂies from both
CAG repeat RNA-based and polyQ protein toxicity. In contrast,
the enhancement of Hsp70 expression in R6/2 mice had only a
modest effect on disease progression [116].
Although the Hdj1/Hsp40 co-chaperone plays an auxiliary role
in Hsp70-driven chaperone cycle, its former overexpression in cells
transfected with the mutant htt gene proved to suppress aggregate
formation and reduce cell death [117]. Likewise, the overexpres-
sion of pairs Hsp70–Hdj1 and Hsp70–Hdj2 was shown to have a
protectiveeffect in a cell model of SBMA. Moreover, the expression
of chaperone pairs not only increased the solubility of the mutant
androgen receptor but also enhanced the function of the protea-
some machinery [118]. Interestingly, Popiel et al. [119] found that
targeted adenovirus infection of the striatum with the hsp40 gene
in R6/2 mice resulted in a reduced accumulation of Htt aggregates
in the nucleus and improved behavioral indicators of animal
health; moreover, secretion of pathogenic polyQ protein from cul-
tured cells was also reduced by Hsp40 overexpression.
Another J domain-containing protein, HSJ1a (DNAJB2a), may
also play an anti-aggregate role. It has been shown that its overex-
pression signiﬁcantly reduces mutant Htt aggregation and en-
hances its solubility. Both J domain and ubiquitin-interacting
domain are important for the inhibition of mutant Htt aggregation.
The ability to nucleate further aggregation is dependent on HSJ1a
binding with mutant Htt, interaction with ubiquitin, and functional
cooperation with Hsp70. Importantly, HSJ1a mediates an increase
in mutant Htt solubility, and its anti-aggregation activity improves
neurological performance in R6/2 mice [120].
5. Targets and drug candidates in polyglutamine diseases
Novel approaches to selective reduction of mutant Htt level in
cells may open new horizons in the treatment of HD and other pol-
yQ diseases. It has been shown that RNA interference (RNAi) tech-
niques discriminate between single nucleotides within dominant,
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(for review, see [121]). In particular, insertion of small interfering
RNA (siRNA) against a single-nucleotide-polymorphism proved
highly efﬁcient in reducing Htt mRNA expression [122]. Viral vec-
tor-mediated short-hairpin RNAi directed against the mutant htt
gene alleviated HD-like neuropathology and abnormal motor
behavior [123] and caused partial reversal of disease progression
in R6/1 HD transgenic mice [124], indicating prospects for clinical
applications of small RNAs. Another approach to speciﬁc and com-
plete inhibition of polyQ protein expression employs novel tech-
nology based on zinc ﬁnger proteins (ZFP). Speciﬁc ZFP were
designed to bind longer CAG repeats more strongly than shorter
ones, and such genetic construct were employed to obtain stably
transfected HD model cells. Stable expression of ZFP was found
to reduce chromosomal expression of the mutant gene at both pro-
tein and mRNA levels. This was achieved inside chromosomes in
the context of endogenous mouse htt genes with variable CAG-
repeat lengths. Viral delivery of ZFP gene construct in R6/2 mice re-
sulted in 60% suppression of target htt gene, consistently with
diminished aggregation, decline in rotarod performance, and alle-
viation of clasping, which provided evidence for the high efﬁciency
of ZFP technology [125].
During the past few years, a great variety of drugs have been of-
fered that recognize various motifs of a polyQ protein molecule
and are targeted at its certain sequence or post-translational mod-
iﬁcation [121]. Among them, speciﬁc antibodies against the polyQ
sequence deserve special attention. They are targeted mainly at the
N-terminal 17-aa sequence of Htt, which is responsible for its
aggregation and toxicity [126]. The scFv-C4 intrabody (see above)
directed against this part of Htt molecule proved to signiﬁcantly
reduce the size and number of aggregates in HD R6/1 transgenic
mice [127].
It may well be that misfolding/aggregation of the expanded pol-
yQ protein can be inhibited by peptides speciﬁcally binding to the
expanded polyQ stretch, resembling the prevention of Ab aggrega-
tion with Ab-binding peptide [128]. Nagai et al. [129]performed
screening of such peptides using the phage display technique and
found that one peptide, QBP1 (SNWKWWPGIFD), selectively binds
to Q62 rather than to ‘‘normal’’ Q19. QBP1was fused with protein
transduction domain (PTD), Antp peptide, and introduced into cells
expressing mutant Htt with different lengths of the polyQ tract.
Treatment with PTD–QBP1 notably inhibited polyQ inclusion body
formation and reduced cytotoxicity in a concentration-dependent
manner. Fused peptides added to food for HD transgenic Drosophila
ﬂies were found to signiﬁcantly prolong their lifespan and inhibit
the formation of inclusion bodies [130]. The lifespan of transgenic
ﬂies expressing both QBP1 and Q92 was prolonged tenfold [131].
Injection of AAV5–QBP1 adenovirus construct into the brain of
HD mice also resulted in signiﬁcant inhibition of inclusion body
formation but had no signiﬁcant therapeutic effect with respect
to motor functions or lifespan duration [132,133].
Chen et al. [134] performed screening of a peptoid library
(#60000) using an amino-terminal fragment of a mutant Htt pro-
tein (Htt-N-82Q) as bait. Peptoid HQP09 was selected and con-
ﬁrmed as a speciﬁc ligand of Htt-N-82Q and Atxn3-77Q mutant
proteins in biochemical experiments. HQP09 and its derivate,
HQP09_9, inhibited aggregation of Htt-N-53Q in vitro and exerted
Ca2+-stabilizing and neuroprotective effects in experiments with
primary striatal neuronal cultures derived from HD mice. The
intracerebroventricular delivery of HQP09 to an HD mouse model
resulted in reduced accumulation of mutant Htt aggregates and
improved motor behavioral outcomes.
The screening of small molecules targeted to mutant polyQ pro-
teins can be also fruitful. For example, screening of the Johns Hop-
kins Clinical Compound Library using httQ72-Luc with Q80(CFP/
YFP) as seeds has allowed identiﬁcation of leﬂunomide, a dihydro-orotate dehydrogenase inhibitor with immunosuppressive and
anti-psoriatic activities, as a novel drug that prevents polyQ aggre-
gation. Leﬂunomide and its active metabolite, teriﬂunomide, inhi-
bit protein aggregation independently of their known role in
pyrimidine biosynthesis, since neither uridine treatment nor other
pyrimidine biosynthesis inhibitors have affected polyQ aggrega-
tion [135].
Recent experiments by Zhang et al. [136] on a Caenorhabditis
elegansmodels have shown that Astragalus membranaceus polysac-
charide (astragalan) has an ability to reduce polyQ aggregation and
modulate aging and proteotoxic stress pathways. Astragalan can
prolong the adult lifespan of wild-type and polyQ nematodes, indi-
cating a relationship between its anti-aging and toxicity-suppress-
ing effects.
In addition to substances directly targeted at polyQ molecules
themselves, there is a great number of factors that have an effect
on proteins damaged or inhibited by these molecules. Some of
these factors are listed in Table 2 and discussed in corresponding
sections of the review.
Thus, the pathogenesis of polyQ diseases is a multiphase pro-
cess in the course of which mutant protein species undergo confor-
mational modulations, which contribute to the diversity of effects
of various polyQ forms directed toward certain systems of cell
physiology. In other words, the multiplicity of polyQ conforma-
tions is combined with the enormous multiplicity of cell lifeguards.
In terms of the target-drug paradigm, this means that a spectrum
of medicines are necessary for preventing the initial aggregation
of polyQ proteins and minimizing their harmful effects on neurons.
Therefore, the best effect in the treatment of polyQ diseases can be
achieved using a combinatorial drug strategy.
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